Year end report
YEAR END REPORT Period from January to December 2017 Peptonic Medical AB (publ) org nr 556776-3064 (www.aktietorget.se, ticker: PMED) 2017 FOURTH QUARTER (Oct-Dec) · Operating loss KSEK -4,753 (-3,016) · Loss per share SEK -0.11 (-0.14) FULL YEAR 2017 (Jan-Dec) · Operating loss KSEK -12,962 (-11,320) · Loss per share SEK -0.30 (-0.55)IMPORTANT EVENTS DURING THE PERIOD · On March 10th, the Company announced that the primary efficacy endpoints of the first part of its phase 2b study, in which the Vagitocin® gel was investigated for the treatment of